Immunohistochemical double staining with estrogen receptor and HER2 on primary breast cancer

  • Authors:
    • Jun Horiguchi
    • Yukio Koibuchi
    • Kotaro Iijima
    • Takashi Yoshida
    • Miho Yoshida
    • Daisuke Takata
    • Tetsunari Oyama
    • Yuichi Iino
    • Yasuo Morishita
  • View Affiliations

  • Published online on: December 1, 2003     https://doi.org/10.3892/ijmm.12.6.855
  • Pages: 855-859
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Immunohistochemical double staining with estrogen receptor (ER) and epidermal growth factor receptor 2 (HER2) was conducted in tissue sample of 125 women with invasive breast cancer. The age at the time of surgery ranged from 28 to 82 years. The tumor size was 2 cm or less in 42 patients and larger than 2 cm in 83. Axillary lymph node status was positive in 53 patients and negative in 72. Estrogen receptor (ER) which was measured using enzyme immunoassay (EIA) was positive in 67 patients, negative in 50 and unknown in 8. Of the 125 patients evaluated, 83 (66.4%) were immunohistochemically positive for ER. ER by immunohistochemistry (IHC) (ER-IHC) was significantly (p<0.01) correlated with ER by EIA (ER-EIA). ER-EIA values in ER-IHC scores were 1.4 fmol/mg protein in score 0, 0.0 in score 1, 19.0 in score 3, 21.2 in score 4, 12.2 in score 5, 17.6 in score 6, 30.0 in score 7 and 114.8 in score 8. ER-EIA values in ER-IHC-score 8 were significantly higher than in scores 0, 2, 3, 4, 5, 6 and 7. Of the 125 patients, 35 (28%) were immunohistologically positive for HER2. HER2 expression was inversely correlated with ER expression. When evaluated even in ER-positive patients, HER2 overexpression was associated with lower ER levels. In this study, we conducted immunohistochemical double staining with ER and HER2, and demonstrated that low ER levels might be one factor in the relative resistance of HER2-positive and ER-positive tumors to hormonal therapy.

Related Articles

Journal Cover

December 2003
Volume 12 Issue 6

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Horiguchi J, Koibuchi Y, Iijima K, Yoshida T, Yoshida M, Takata D, Oyama T, Iino Y and Morishita Y: Immunohistochemical double staining with estrogen receptor and HER2 on primary breast cancer. Int J Mol Med 12: 855-859, 2003.
APA
Horiguchi, J., Koibuchi, Y., Iijima, K., Yoshida, T., Yoshida, M., Takata, D. ... Morishita, Y. (2003). Immunohistochemical double staining with estrogen receptor and HER2 on primary breast cancer. International Journal of Molecular Medicine, 12, 855-859. https://doi.org/10.3892/ijmm.12.6.855
MLA
Horiguchi, J., Koibuchi, Y., Iijima, K., Yoshida, T., Yoshida, M., Takata, D., Oyama, T., Iino, Y., Morishita, Y."Immunohistochemical double staining with estrogen receptor and HER2 on primary breast cancer". International Journal of Molecular Medicine 12.6 (2003): 855-859.
Chicago
Horiguchi, J., Koibuchi, Y., Iijima, K., Yoshida, T., Yoshida, M., Takata, D., Oyama, T., Iino, Y., Morishita, Y."Immunohistochemical double staining with estrogen receptor and HER2 on primary breast cancer". International Journal of Molecular Medicine 12, no. 6 (2003): 855-859. https://doi.org/10.3892/ijmm.12.6.855